Investegate |INVENTIVA Announcements | INVENTIVA: Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

Investegate announcements from INVENTIVA, Inventiva announces changes to the clinical development of lanifibranor, including plans for a new Phase III trial in patients with NASH and compensated cirrhosis

Related Keywords

New York ,United States ,Russia ,Ukraine ,Michael Cooreman ,Sven Francque ,Pascaline Clerc ,Donna Cryer ,Tarun Sanyal ,Aude Lepreux ,Patricial Bank ,Brunswick Group ,Exchange Commission On ,Antwerp University Hospital ,Virginia Commonwealth University ,Drug Administration ,Stravitz Sanyal Institute For Liver Disease ,Metabolic Health ,Nasdaq ,Global External Affairs ,Global Liver Institute ,Long Island City ,Euronext Paris ,Fast Track ,Breakthrough Therapy ,Chief Medical Officer ,Stravitz Sanyal Institute ,Liver Disease ,Nasdaq Global Market ,Global External ,Roquet Montegon ,Private Securities Litigation Reform Act ,Universal Registration Document ,Des March ,Annual Report ,Exchange Commission ,Investegate Announcements ,Investegate Company Announcements ,Inventiva ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,